Lumos Diagnostics CEO Doug Ward joined Steve Darling from Proactive to discuss the expanding commercial rollout of the company's FebriDx rapid diagnostic test, with deployment now underway at more than 30 U.S. urgent care sites and three additional major healthcare groups advancing through clinical and economic validation.
Together, the four priority healthcare accounts represent more than 430 potential locations and an estimated 2.6 million acute respiratory infection patient visits annually, supporting Lumos' strategy of targeting the 100 largest U.S. urgent care groups, which account for roughly 40% of all urgent care sites nationwide.
One of the company's latest customers, a leading regional urgent care provider owned by a major U.S. health system, has agreed to deploy FebriDx across its network of more than 30 clinics. Lumos estimates the network treats approximately 200,000 acute respiratory infection cases each year, where FebriDx is expected to improve respiratory triage, support antibiotic stewardship, and standardize clinical workflows.
Lumos has also introduced a four-stage commercial framework that moves customers from initial qualification and clinical validation through network rollout and ultimately into routine clinical adoption. The model builds on the company's success with WellStreet Urgent Care, where an initial pilot expanded to 44 locations and created a pathway for potential deployment across a network of more than 165 sites.
All U.S. sales of FebriDx are conducted through Lumos' exclusive distribution partnership with Phase Scientific, with Lumos recognizing revenue when products are shipped to the distributor.
Podden och tillhörande omslagsbild på den här sidan tillhör
Proactive. Innehållet i podden är skapat av Proactive och inte av,
eller tillsammans med, Poddtoppen.
